195 related articles for article (PubMed ID: 24304938)
21. Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the Atrial Fibrillation and Congestive Heart Failure Trial.
O'Meara E; Khairy P; Blanchet MC; de Denus S; Pedersen OD; Levesque S; Talajic M; Ducharme A; White M; Racine N; Rouleau JL; Tardif JC; Roy D;
Circ Heart Fail; 2012 Sep; 5(5):586-93. PubMed ID: 22798522
[TBL] [Abstract][Full Text] [Related]
22. Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
Shen L; Jhund PS; Docherty KF; Petrie MC; Anand IS; Carson PE; Desai AS; Granger CB; Komajda M; McKelvie RS; Pfeffer MA; Solomon SD; Swedberg K; Zile MR; McMurray JJV
JACC Heart Fail; 2019 May; 7(5):418-427. PubMed ID: 30981744
[TBL] [Abstract][Full Text] [Related]
23. Galectin-3 and the Mineralocorticoid Receptor Antagonist Canrenone in Mild Heart Failure.
Clemenza F; Masson S; Conaldi PG; Di Carlo D; Boccanelli A; Mureddu GF; Gonzini L; Lucci D; Maggioni AP; Di Lenarda A; Nicolis EB; Vanasia M; Latini R;
Circ J; 2017 Sep; 81(10):1543-1546. PubMed ID: 28855452
[TBL] [Abstract][Full Text] [Related]
24. Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial.
Beygui F; Cayla G; Roule V; Roubille F; Delarche N; Silvain J; Van Belle E; Belle L; Galinier M; Motreff P; Cornillet L; Collet JP; Furber A; Goldstein P; Ecollan P; Legallois D; Lebon A; Rousseau H; Machecourt J; Zannad F; Vicaut E; Montalescot G;
J Am Coll Cardiol; 2016 Apr; 67(16):1917-27. PubMed ID: 27102506
[TBL] [Abstract][Full Text] [Related]
25. Galectin-3 and cardiac function in survivors of acute myocardial infarction.
Weir RA; Petrie CJ; Murphy CA; Clements S; Steedman T; Miller AM; McInnes IB; Squire IB; Ng LL; Dargie HJ; McMurray JJ
Circ Heart Fail; 2013 May; 6(3):492-8. PubMed ID: 23505301
[TBL] [Abstract][Full Text] [Related]
26. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community.
Ho JE; Liu C; Lyass A; Courchesne P; Pencina MJ; Vasan RS; Larson MG; Levy D
J Am Coll Cardiol; 2012 Oct; 60(14):1249-56. PubMed ID: 22939561
[TBL] [Abstract][Full Text] [Related]
27. Galectin 3: association to neurohumoral activity, echocardiographic parameters and renal function in outpatients with heart failure.
Stoltze Gaborit F; Bosselmann H; Kistorp C; Iversen K; Kumler T; Gustafsson F; Goetze JP; Sölétormos G; Tønder N; Schou M
BMC Cardiovasc Disord; 2016 May; 16():117. PubMed ID: 27246703
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of aldosterone and cortisol in patients hospitalized for acutely decompensated chronic heart failure with and without mineralocorticoid receptor antagonism.
Güder G; Hammer F; Deutschbein T; Brenner S; Berliner D; Deubner N; Bidlingmaier M; Ertl G; Allolio B; Angermann CE; Fassnacht M; Störk S
J Card Fail; 2015 Mar; 21(3):208-16. PubMed ID: 25573831
[TBL] [Abstract][Full Text] [Related]
29. Mineralocorticoid receptor antagonist initiation during admission is associated with improved outcomes irrespective of ejection fraction in patients with acute heart failure.
Beldhuis IE; Damman K; Pang PS; Greenberg B; Davison BA; Cotter G; Gimpelewicz C; Felker GM; Filippatos G; Teerlink JR; Metra M; Voors AA; Ter Maaten JM
Eur J Heart Fail; 2023 Sep; 25(9):1584-1592. PubMed ID: 37462255
[TBL] [Abstract][Full Text] [Related]
30. Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction.
Serenelli M; Jackson A; Dewan P; Jhund PS; Petrie MC; Rossignol P; Campo G; Pitt B; Zannad F; Ferreira JP; McMurray JJV
JACC Heart Fail; 2020 Mar; 8(3):188-198. PubMed ID: 31926854
[TBL] [Abstract][Full Text] [Related]
31. Association Between Mineralocorticoid Receptor Antagonist Use and Outcome in Myocardial Infarction Patients With Heart Failure.
Löfman I; Szummer K; Olsson H; Carrero JJ; Lund LH; Jernberg T
J Am Heart Assoc; 2018 Jul; 7(14):. PubMed ID: 29980521
[TBL] [Abstract][Full Text] [Related]
32. Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial).
Vaduganathan M; Dei Cas A; Mentz RJ; Greene SJ; Khan S; Subacius HP; Chioncel O; Maggioni AP; Konstam MA; Senni M; Fonarow GC; Butler J; Gheorghiade M;
Am J Cardiol; 2014 Sep; 114(5):743-50. PubMed ID: 25060414
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH.
van der Velde AR; Gullestad L; Ueland T; Aukrust P; Guo Y; Adourian A; Muntendam P; van Veldhuisen DJ; de Boer RA
Circ Heart Fail; 2013 Mar; 6(2):219-26. PubMed ID: 23395934
[TBL] [Abstract][Full Text] [Related]
34. Association of spironolactone use with all-cause mortality in heart failure: a propensity scored cohort study.
Lund LH; Svennblad B; Melhus H; Hallberg P; Dahlström U; Edner M
Circ Heart Fail; 2013 Mar; 6(2):174-83. PubMed ID: 23386667
[TBL] [Abstract][Full Text] [Related]
35. Heart Rate or Beta-Blocker Dose? Association With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction: Results From the HF-ACTION Trial.
Fiuzat M; Wojdyla D; Pina I; Adams K; Whellan D; O'Connor CM
JACC Heart Fail; 2016 Feb; 4(2):109-115. PubMed ID: 26519996
[TBL] [Abstract][Full Text] [Related]
36. Mineralcorticoid Receptor Antagonist Withdrawal for Hyperkalemia and Mortality in Patients with Heart Failure.
Lisi F; Parisi G; Gioia MI; Amato L; Bellino MC; Grande D; Massari F; Caldarola P; Ciccone MM; Iacoviello M
Cardiorenal Med; 2020; 10(3):145-153. PubMed ID: 31982865
[TBL] [Abstract][Full Text] [Related]
37. Mineralocorticoid receptor antagonists for heart failure: a real-life observational study.
Bruno N; Sinagra G; Paolillo S; Bonomi A; Corrà U; Piepoli M; Veglia F; Salvioni E; Lagioia R; Metra M; Limongelli G; Cattadori G; Scardovi AB; Carubelli V; Scrutino D; Badagliacca R; Guazzi M; Raimondo R; Gentile P; Magrì D; Correale M; Parati G; Re F; Cicoira M; Frigerio M; Bussotti M; Vignati C; Oliva F; Mezzani A; Vergaro G; Di Lenarda A; Passino C; Sciomer S; Pacileo G; Ricci R; Contini M; Apostolo A; Palermo P; Mapelli M; Carriere C; Clemenza F; Binno S; Belardinelli R; Lombardi C; Perrone Filardi P; Emdin M; Agostoni P
ESC Heart Fail; 2018 Jun; 5(3):267-274. PubMed ID: 29397584
[TBL] [Abstract][Full Text] [Related]
38. Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF.
Shen L; Kristensen SL; Bengtsson O; Böhm M; de Boer RA; Docherty KF; Inzucchi SE; Katova T; Køber L; Kosiborod MN; Langkilde AM; Lindholm D; Martinez MFA; O'Meara E; Nicolau JC; Petrie MC; Ponikowski P; Sabatine MS; Schou M; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV
JACC Heart Fail; 2021 Apr; 9(4):254-264. PubMed ID: 33549554
[TBL] [Abstract][Full Text] [Related]
39. Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials.
Rossello X; Ariti C; Pocock SJ; Ferreira JP; Girerd N; McMurray JJV; Van Veldhuisen DJ; Pitt B; Zannad F
Clin Res Cardiol; 2019 May; 108(5):477-486. PubMed ID: 30264282
[TBL] [Abstract][Full Text] [Related]
40. MRAs in Elderly HF Patients: Individual Patient-Data Meta-Analysis of RALES, EMPHASIS-HF, and TOPCAT.
Ferreira JP; Rossello X; Eschalier R; McMurray JJV; Pocock S; Girerd N; Rossignol P; Pitt B; Zannad F
JACC Heart Fail; 2019 Dec; 7(12):1012-1021. PubMed ID: 31779922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
